Should I buy Revvity (RVTY) stock or is it too late?

Revvity · Health Care · price $130

⭐ What the most reliable analysts say

No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.

Firm-by-firm track record on Revvity

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Raymond James	44 %	+3.5 %	9	$115 -11%
Baird	20 %	-8.8 %	5	$125 -4%

In short — Should you invest in Revvity? Is it too late, still worth it? Analysts are split (43% buy, median target $105, i.e. -19%). But the valuation is stretched (P/E ~62), it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

Few solid positives from analysts right now: of 7 ratings, only 3 buys, and the median price target ($105) is -19% below the price ($130). Caution prevails.

⚠️ Reasons to hesitate

Even the most reliable firm on RVTY, Evercore ISI Group (100% hit rate, 2 scored calls), only targets $126 (call made on August 5, 2026, maturing on August 5, 2027) (-3%) in its most recent call, and $106 (call made on October 7, 2025, maturing on October 7, 2026) (-18%) in the one coming due soonest. The stock may already have run past its target.
The consensus is not unanimous: of 7 ratings, 4 are neutral.
Limited upside: the median target is only -19% from the current price.
High valuation (P/E ~62): strong growth is already "priced in", leaving little room for error.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
Negligible dividend (0.3% yield): your return depends mostly on price appreciation.

The analyst consensus on RVTY

Median target $105 (-19%) · 7 ratings · Hold consensus

Strong Buy00%

Buy343%

Hold457%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Revvity now?

We won't decide for you. The facts: 43% of analysts rate it a buy, median target $105 (-19%), and Evercore ISI Group (most reliable on RVTY, 100%) targets $126. Weigh that against valuation (P/E ~62). This is not personalized advice.

Is it too late to invest in Revvity?

The stated upside is small: the median target ($105) sits just -19% from the price ($130) (most reliable on RVTY: Evercore ISI Group, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Revvity still worth investing in?

It depends on the gap between the price ($130) and its estimated value: analysts target $105 on median (-19%), with 43% buys (most reliable on RVTY: Evercore ISI Group, 100%). Cross-check with their real reliability on RVTY and the cautions above. Information, not advice.

What's the main risk in buying RVTY?

Even the most reliable firm on RVTY, Evercore ISI Group (100% hit rate, 2 scored calls), only targets $126 (call made on August 5, 2026, maturing on August 5, 2027) (-3%) in its most recent call, and $106 (call made on October 7, 2025, maturing on October 7, 2026) (-18%) in the one coming due soonest. The stock may already have run past its target.

→ Go deeper: the full Revvity profile (consensus, analyst reliability, price target, performance).